Cubist To Seek Cubicin sNDA Priority Review For Endocarditis, Bacteremia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cubist plans to request a priority review for an sNDA it will submit by year-end for use of its Cubicin antibiotic for endocarditis and bacteremia